Context Therapeutics Inc. · NASDAQ:CNTX
Context Therapeutics — Investor Presentation (March 2026)
35 slides from Context Therapeutics's investor presentation, Mar 23, 2026
Slide 1: March 2026 Corporate Presentation: Advancing T Cell Engagers for Solid Tumors
March 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances
Slide 3: Building a Leading T cell Engager (TCE) Pipeline
Building a Leading T cell Engager (TCE) Pipeline Executive Summary Strategy Developing potentially best-in-class TCE for solid tumors • Tumor antigens that are clinically validated by antibody drug conjugates (ADC) or chimeric antigen receptor T cell therapy (CAR-T) • Limited or weak competition add
Slide 4: Pipeline Overview
Executive Summary Pipeline Overview Context Therapeutics Inc. - March 20264 PROGRAM TARGET ADDRESSABLE MARKET (U.S. ONLY) DISCOVERY DEVELOPMENT PHASE 1 PHASE 2 CTIM-76 Claudin 6 (CLDN6) > 50,000 patients CT-95 Mesothelin (MSLN) > 100,000 patients CT-202 Nectin-4 > 125,000 patients Ph 1a interim data
Slide 5: Context is Positioned to Develop the Next Generation of Transformative T Cell Engagers
Context is Positioned to Develop the Next Generation of Transformative T Cell Engagers Potential to expand into early treatment lines through synergistic drug combinations Executive Summary Context Therapeutics Inc. - March 20265 Synergistic Combination ApproachesOptimized Novel Monotherapies CTIM-7
Slide 6: T Cell Engager Strategy
T Cell Engager Strategy Context Therapeut ics Inc . - March 20266
Slide 7: T Cell Engaging (TCE) Bispecific Antibodies
T Cell Engaging (TCE) Bispecific Antibodies T Cell Engager Strategy Context Therapeutics Inc. - March 20267 Mechanism of Action T-cell engagers (TCEs) are bispecific antibodies designed to redirect cytotoxic T lymphocytes toward malignant cells. These molecules simultaneously bind to a tumor-associa
Slide 8: FDA Approvals for TCE for Solid and Liquid Tumors
10 FDA Approvals for TCE for Solid and Liquid Tumors Recently approved TCE have had strong initial commercial launches T Cell Engager Strategy Context Therapeutics Inc. - March 20268 2024202320222014 2025 Product Target 2025 Revenue1 Blincyto CD19 x CD3 $1,559 million Imdelltra DLL3 x CD3 $936 milli
Slide 9: TCE Success in Solid Tumors
TCE Success in Solid Tumors Asset Tarlatamab (AMG757) HPN328 QLS31905 IBI389 VIR-5500 JANX007 JNJ-78278343 Xaluritamig (AMG509) Ubamatamab (REGN4018) Target x Effector DLL3 x CD3 DLL3 x CD3 CLDN18.2 x CD3 CLDN18.2 x CD3 PSMA x CD3 PSMA x CD3 KLK2 x CD3 STEAP1 x CD3 MUC16 x CD3 Cancer Indication Smal
Slide 10: CTIM-76 CLDN6 x CD3 bispecific antibody
CTIM-76 CLDN6 x CD3 bispecific antibody Context Therapeut ics Inc . - March 202610
Slide 11: CLDN6 Therapies Have the Potential to Reach a Large Patient Population
CLDN6 Therapies Have the Potential to Reach a Large Patient Population >50,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CTIM-76 Program 11 Context Therapeutics Inc. - March 2026 Initial indications of interest based on: • CLDN6 prevalence • Patient population size •
Slide 12: CLDN6 is an Attractive Target for Immunotherapy
CLDN6 is an Attractive Target for Immunotherapy • CLDN6 is an oncofetal protein. Normally present at higher levels during embryonic development • Turned off or have low levels of expression in adult tissues • Expression increases with cancer disease stage • Tetraspan protein; does not readily intern
Slide 13: CTIM-76: Claudin x CD3 T cell Engaging Bispecific Antibody
CTIM-76: Claudin 6 x CD3 T cell Engaging (TCE) Bispecific Antibody Optimized structure for CLDN6 selectivity, potency, and manufacturability • Highly selective CLDN6 binding fragment antibody-binding (Fab) arm • Immunostimulatory CD3 binding single-chain fragment variable (scFv) domain is functional
Slide 14: CTIM-76 is a Highly Selective and Potent CLDN6 x CD3 Bispecific Antibody
CTIM-76 Program CTIM-76 is a Highly Selective and Potent CLDN6 x CD3 Bispecific Antibody Context Therapeutics Inc. - March 202614 Selectivity Potency In Vivo Efficacy • CTIM-76 CLDN6 EC50 of 3.41 nM (binding) • CTIM-76 preferentially binds to CLDN6 over CLDN3/4/9 • CLDN3/4/6/9 were transiently trans
Slide 15: CTIM-76 Phase 1a Dose Escalation Trial
CTIM-76 Phase 1a Dose Escalation Trial Target population • Ovarian, endometrial and testicular cancer relapsed to standard of care • CLDN6+ positive via IHC (≥10% 1+ staining) Trial objectives • Assess safety and tolerability • Pharmacokinetic and pharmacodynamic data • Evaluate preliminary anti-tum
Slide 16: Summary of Preliminary Data from Ongoing Phase 1a Trial of CTIM-76
Summary of Preliminary Data from Ongoing Phase 1a Trial of CTIM-76 as of October 2025 Context anticipates providing updated interim Phase 1a data in June 2026 CTIM-76 Program Context Therapeutics Inc. - March 202616 12 patients enrolled: ovarian (7); testicular (3); endometrial (2) Median of 4 previ
Slide 17: CTIM-76 Competitive Landscape: Clinical Programs
Clinical Programs Discontinued CTIM-76 XmAb541 ARC101 BGB-B455 AMG794 SAIL66 Company Context Xencor Third Arc BeOne Amgen Chugai Stage Ph 1 Ph 1 Ph 1 Ph 1 Ph 11 Ph 1 Bispecific Format 1 + 1 2 + 1 1 + 1 1 + 1 HLE Bite Dual Specific Fab CLDN3/4/9 Selectivity High1 Moderate2 High3 Not Disclosed4 High6
Slide 18: CT-95 MSLN x CD3 bispecific antibody
CT-95 MSLN x CD3 bispecific antibody Context Therapeut ics Inc . - March 202618
Slide 19: MSLN Therapies Have the Potential to Reach a Large Patient Population
MSLN Therapies Have the Potential to Reach a Large Patient Population >100,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CT-95 Program 19 Context Therapeutics Inc. - March 2026 Selected Cancer indications Incidence (US Only) R/R Incidence MSLN Positive MSLN Med/High
Slide 20: MSLN Target Biology
MSLN Target Biology Shed mesothelin (sMSLN) in tumor microenvironment requires a creative solution to overcome CT-95 Program Context Therapeutics Inc. - March 202620 MSLN is bound to tumor cells via a GPI-anchor Like many GPI-anchored proteins, MSLN can be cut into smaller fragments1,2 The MSLN gene
Slide 21: CT-95: MSLN x CD3 T cell Engaging Bispecific Antibody
CT-95: MSLN x CD3 T cell Engaging (TCE) Bispecific Antibody Novel design to overcome mesothelin (MSLN) sink • Binds to membrane-proximal MSLN epitope • Affinity tuned MSLN binding • Cooperative binding results in high affinity binding of CT-95 to tumor Potentially wide therapeutic window • No crossl
Slide 22: Cytotoxicity in the Presence of Soluble MSLN
Cytotoxicity in the Presence of Soluble MSLN CT-95 Intended to Overcome MSLN Sink HPN-536 (Harpoon Therapeutics) binds to soluble MSLN (sMSLN) in a dose proportional manner, limiting therapeutic exposure CT-95 Program Context Therapeutics Inc. - March 202622 CT-95 +10nM sMSLN +30nM sMSLN HPN-536 +10
Slide 23: CT-95 Phase 1a/b Study
CT-95 Phase 1a/b Study An open-label, multi-center, dose escalation / expansion, safety, and PK study (NCT06756035) CT-95 Program 23 Context Therapeutics Inc. - March 2026 Trial status information provided as of March 20, 2026 0.3 µg/kg 0.18 0.6 µg/kg 0.27 0.9 µg/kg 0.36 1.2 µg/kg 0.48 1.6 µ
Slide 24: CT-95 Competitive Landscape
CT-95 Competitive Landscape CT-95 is avidity enhanced, affinity tuned, and binds to membrane-bound MSLN CT-95 Program Context Therapeutics Inc. - March 202624 CT-95 AMG-305 HPN-536 JNJ-79032421 ZW171 Company Context Amgen4 Harpoon1 JNJ Zymeworks2,3 Format 2 + 2 1 + 1 + 2 CDH3 + MSLN dBiTE TriTAC 1+1
Slide 25: CT-202 Nectin-4 x CD3 bispecific antibody
CT-202 Nectin-4 x CD3 bispecific antibody Context Therapeut ics Inc . - March 202625
Slide 26: Nectin-4 Therapies Have the Potential to Reach a Large Patient Population
Nectin-4 Therapies Have the Potential to Reach a Large Patient Population >125,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CT-202 Program 26 Context Therapeutics Inc. - March 2026 Selected Cancer indications Incidence (US Only) R/R Incidence Nectin-4 Positive Necti
Slide 27: CT-202: Nectin-4 x CD3 T cell Engaging Bispecific Antibody
CT-202: Nectin-4 x CD3 T cell Engaging (TCE) Bispecific Antibody CT-202 Program Context Therapeutics Inc. - March 202627 α-Nectin-4 Fab α-CD3 scFv IgG1 backbone Silenced Fc Novel design incorporating logic gating to spare Nectin-4 in normal tissue • Because of its expression in healthy epidermal ker
Slide 28: Two-Pronged Approach to Overcoming Nectin-4 Expression in Skin
Two-Pronged Approach to Overcoming Nectin-4 Expression in Skin CT-202 Program 28 Logic Gating Through pH Dependency + Increased Target Selectivity Through Avidity 1 Chang, PNAS, 2021 CD3 Potent T cell activationNo T cell activation High on-/off-rate when bound to Nectin-4 monomer Avidity-enhanced Ne
Slide 29: CT-202 is Highly Active and Well Tolerated Across In Vivo Models
CT-202 is Highly Active and Well Tolerated Across In Vivo Models CT-202 Program Context Therapeutics Inc. - March 202629 Complete Tumor Regressions CT-202 demonstrated similar efficacy in BT474 breast cancer xenograft compared to enfortumab TCE control antibodies in mice Reduced Cytokine Release CT-
Slide 30: CT-202 Competitive Landscape
CT-202 Competitive Landscape Competitor TCE programs lack conditional activation, avidity enhancement, and high potency immune activator Context Therapeutics Inc. - March 202630 Company Context Therapeutics Bicycle Therapeutics Rondo Therapeutics Asset CT-202 BT74801,2 RNDO-5643 Format 2 + 2 (pH dep
Slide 31: Corporate
Corporate 31 Context Therapeut ics Inc . - March 2026
Slide 32: Anticipated Key Milestones in 2026-2027
Anticipated Key Milestones in 2026-2027 • Multiple potential data inflection points over the next 18 months • Anticipated cash runway into mid-2027 Corporate PROGRAM target 1H 2026 2H 2026 1H 2027 2H 2027 CTIM-76 Claudin 6 (CLDN6) CT-95 Mesothelin (MSLN) CT-202 Nectin-4 Ph 1a Dose Escalation Ph 1a Q
Slide 33: Experienced Leadership Team
Corporate Experienced Leadership Team Experienced management team Clinical team has developed T cell therapies Our management team is supported by a Board with deep oncology experience Focus on Execution Martin Lehr CEO and Director Alex Levit, Esq Chief Legal Officer Karen Chagin, MD Chief Medical
Slide 34: Advancing T Cell Engagers for Solid Tumors
Advancing T Cell Engagers for Solid Tumors © Context Therapeutics 2026
Slide 35: Glossary
Glossary ADC Antibody drug conjugate AE Adverse event CAR-T Chimeric antigen receptor T cell therapy CD3 Cluster of differentiation 3 CLDN Claudin CRS Cytokine release syndrome DLT Dose limiting toxicity Fab Fragment antigen-binding region FIH First-in-human FPI First Patient In (dosed) FRα Folate r
Context Therapeutics — Investor Presentation (March 2026) on 6ix